MKI67 and glioblastoma: This, accompanied by increased Ki67+ GBM cells, may indicate that LV-intermediate tumors were located in a “sweet spot” where the tumors are able to take advantage of neurogenic factors contained within the SVZ niche without leading to significant neurogenic disruption.